Erratum to Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms
Erratum to: Ann Transl Med 2022;10:490.
The article (1) titled “Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms” (doi: 10.21037/atm-22-1459) unfortunately contains an error in Figure 8. In Figure 8A, the images representing the tumorigenesis of AML xenograft mice treated with venetoclax and HHT alone or in combination were misused.
Figure 8A of the original article:
Figure 8A after correction:
The correct version of Figure 8 was shown below:
The authors confirmed this error did not significantly affect either the results or the conclusions of the paper.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Yuan F, Li D, Li G, et al. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms. Ann Transl Med 2022;10:490. [Crossref] [PubMed]
